Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Pediatr Gastroenterol Nutr ; 78(2): 280-288, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38374550

ABSTRACT

OBJECTIVES: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) often requiring endoscopic evaluations, which can be uncomfortable and costly, especially for children. This study aimed to evaluate the diagnostic accuracy of a noninvasive approach combining fecal calprotectin (FCP), colonic ultrasonography (US), and colon capsule endoscopy (CCE) compared with standard ileocolonoscopy in pediatric UC. METHODS: UC children were enrolled and underwent FCP and US on Day 0, followed by CCE on Day 1 and ileocolonoscopy on Day 2. All procedures were performed by operators who were blinded to the patient's clinical history and all test results. The accuracy for disease activity and extension of each technique and their combination was assessed and compared. Tolerability and safety were also evaluated. RESULTS: Thirty-two patients were enrolled (15 males, mean age 13.2 ± 3.2 years). CCE showed a sensitivity of 95% and specificity of 100% in detecting colonic inflammation, with positive predictive value (PPV) and negative predictive value (NPV) of 100% and 92%, respectively. US demonstrated a sensitivity of 85% and specificity of 92%, with PPV and NPV of 94% and 79%. The combination of FCP, US, and CCE achieved 95% sensitivity and 100% specificity, with PPV of 100% and NPV of 92%. The noninvasive approach was better tolerated than colonoscopy (p < 0.05), and no serious adverse events were reported. CONCLUSION: The noninvasive approach combining fecal calprotectin (FCP), ultrasonography, and colon capsule endoscopy demonstrated high diagnostic accuracy and better tolerability compared with standard ileocolonoscopy in pediatric ulcerative colitis follow-up. Further multicenter studies are needed to confirm these findings and evaluate the reproducibility of this noninvasive approach.


Subject(s)
Colitis, Ulcerative , Male , Child , Humans , Adolescent , Colitis, Ulcerative/diagnostic imaging , Prospective Studies , Follow-Up Studies , Reproducibility of Results , Severity of Illness Index , Colonoscopy/methods , Feces , Leukocyte L1 Antigen Complex , Biomarkers
2.
Clin Gastroenterol Hepatol ; 20(12): 2905-2907.e2, 2022 12.
Article in English | MEDLINE | ID: mdl-34555518

ABSTRACT

Eosinophilic esophagitis (EoE) is an immune-mediated condition characterized by symptoms of esophageal dysfunction and an eosinophilic inflammation of the esophagus.1 Swallowed topical steroids represent one of the possible strategies for inducing and maintaining remission in EoE.2 To date, a validated maintenance strategy has yet to be defined, especially in children. The available evidence suggests decreasing the dose after a successful induction therapy.3 No study has reported the efficacy of a continuous progressive dose reduction; thus, it is unknown if all patients need to use the same dosages and for how long.4,5.


Subject(s)
Eosinophilic Esophagitis , Child , Humans , Eosinophilic Esophagitis/diagnosis , Budesonide , Glucocorticoids/therapeutic use , Steroids/therapeutic use
3.
Dig Dis Sci ; 64(6): 1571-1578, 2019 06.
Article in English | MEDLINE | ID: mdl-30659470

ABSTRACT

BACKGROUND: A new prepared oral viscous budesonide (PVB) has been effective in inducing clinical and histological remission in pediatric eosinophilic esophagitis (EoE). AIMS: To evaluate the efficacy of a 12-week maintenance therapy on clinical, endoscopic, and histological remission using half of the dose used in the induction therapy. METHODS: We prospectively enrolled pediatric patients with active EoE. After 12 weeks of induction therapy with PVB (< 150 cm: 2 mg/day; ≥ 150 cm: 4 mg/day) patients received a maintenance dose of half of the dose used in the induction therapy (1 mg or 2 mg) for another 12 weeks. A 12-week follow-up was then performed in all patients after the end of therapy. Endoscopy was performed at weeks 0, 12, 24, and 36. Symptoms, endoscopy, and histology scores were also calculated. Serum cortisol was evaluated during the treatment period. RESULTS: We enrolled 20 children (15 males; median age 10 years; range 4-17). After the 12-week induction therapy 18 patients (90%) were in remission, with a significant decrease in the median peak of eosinophil count/HPF as well as a marked reduction in clinical, endoscopic, and histological scores (p < 0.01). At the end of the maintenance therapy (week 24), 17 patients (85%) were still in remission, while there were only 9 at week 36 (45%). No significant changes in cortisol levels were observed during the study period. CONCLUSIONS: The 12-week maintenance treatment with the half the dose of PVB was effective in sustaining remission at week 24; however, no reduction in the rate of relapse after suspension of treatment occurred.


Subject(s)
Budesonide/administration & dosage , Eosinophilic Esophagitis/drug therapy , Glucocorticoids/administration & dosage , Administration, Oral , Adolescent , Age of Onset , Budesonide/adverse effects , Child , Child, Preschool , Drug Administration Schedule , Drug Compounding , Eosinophilic Esophagitis/immunology , Eosinophilic Esophagitis/pathology , Female , Glucocorticoids/adverse effects , Humans , Maintenance Chemotherapy , Male , Pharmaceutical Solutions , Pilot Projects , Prospective Studies , Recurrence , Remission Induction , Rome , Time Factors , Treatment Outcome , Viscosity
SELECTION OF CITATIONS
SEARCH DETAIL